Journal of the Korea Convergence Society (한국융합학회논문지)

Korea Convergence Society (한국융합학회)
권호 표지
DOI QR코드

DOI QR Code

The using practices of antipsychotics for people with intellectual disabilities in Japan

일본의 지적장애인에 대한 항정신약의 사용 실태

  • Kim, Mi-SuK (Special Education, Teachers College, Baekseok University)
  • 김미숙 (백석대학교 사범학부 특수교육과)
  • Received : 2018.10.04
  • Accepted : 2018.12.20
  • Published : 2018.12.28
Download PDF
⟨ Previous Next ⟩

Abstract

In Korea, there has been no national research on the use of antipsychotics for people with intellectual disabilities(I.D); therefore, it is difficult to identify the problems or to find solutions for problems in using antipsychotics. So, the purpose of this study analyze research findings on the use of antipsychotics for people with I.D in Japan. This research method compared and analyzed the results of research published in the journal J-STAGE and Medical Online and studied a cohort results using data. The results of the analysis are as follows. First, many antipsychotic drugs are prescribed to people with I.D, but it is difficult to accurately assess the effectiveness of the treatments. Second, it is not easy to detect side effects. Third, the potential side effects of drug interactions have been raised. The results was emphasized the need of research that accurately evaluate the drugs in survey of actual situation to ensure more safe use of antipsychotics to peoples with I.D in Korea.

한국은 지적장애인에 대한 항정신약의 사용 실태를 국가적으로 조사한 연구가 없어 항정신약 사용의 문제점이나 개선사항을 파악하기 어렵다. 따라서 본 연구의 목적은 지적장애인에게 처방되는 항정신약의 사용 실태를 국가적으로 조사한 일본의 동향을 분석하여 한국에서의 조사를 위한 기초 자료를 제공하고자 한다. 연구 방법은 일본의 J-STAGE, 메디칼온라인, 코호트 연구에서 정신박약, 정신지체, 지적장애, Psychotropic, Antipsychotic, 행동장애로 검색하여 유효한 논문들을 비교 분석하였다. 연구 결과는 첫째, 지적장애인에게 처방되는 다양한 항정신약물의 치료 효과에 대한 정확한 평가가 곤란하며, 둘째, 부작용을 쉽게 알아내지 못하는 동향이 높으며 셋째, 약물 간의 상호작용에 의한 부작용의 가능성에 대한 문제가 제기되고 있음을 알 수 있었다. 이 결과는 향후 한국의 지적장애인에게 보다 안전한 항정신약의 사용을 보장하기 위한 연구와 조사는 물론 개선 방법을 모색하는데 기초 자료가 될 것이다.

Keywords

OHHGBW_2018_v9n12_207_f0001.png 이미지

Fig. 1. Details of the prescription for central nervous treatment

OHHGBW_2018_v9n12_207_f0002.png 이미지

Fig. 2. Trends of the use on antipsychotic drugs in children of intellectual disabilities with hyperactivity disorder

OHHGBW_2018_v9n12_207_f0003.png 이미지

Fig. 3. Prescription rate of antipsychotic drugs

OHHGBW_2018_v9n12_207_f0004.png 이미지

Fig. 4. Number of days of antipsychotic prescription and multiple prescription rate of antipsychotic drug

Table 1. Analysis of J-STAGE

OHHGBW_2018_v9n12_207_t0001.png 이미지

Table 2. The antipsychotic in high-frequency of use

OHHGBW_2018_v9n12_207_t0002.png 이미지

Table 3. Comparison of use ratio of psychotropic drug

OHHGBW_2018_v9n12_207_t0003.png 이미지

Table 4. Characteristic of analysis subject

OHHGBW_2018_v9n12_207_t0004.png 이미지

References

  1. K M. Chitty et al. (2016). Central nervous system medication use in older adults with intellectual disability: Results from the successful ageing in intellectual disability study. Aust NZJ Psychiatry, 50(4), 352-362. https://doi.org/10.1177/0004867415587951
  2. N. D. Goli et al. (2016). Intellectual Disability in Children; a Systematic Review. Quarterly of International Archives of Health Sciences. 3(2), 27-36. https://doi.org/10.18869/IAHS.3.2.27
  3. S. L. Einfeld et al. (2011). Comorbidity of intellectual disability and mental disorder in children and adolescents: a systematic review. J Intellect Dev Disabil., 36(2), 137-143. https://doi.org/10.1080/13668250.2011.572548
  4. Y. H. Kang. (2008). Encyclopedia of Life Science. Academy Books.
  5. M. A Song & H. J. Hong. (2013). Use of Antipsychotics in Attention-Deficit Hyperactivity Disorder. Korean College of Neuropsychopharmcology, establishment 11-17.
  6. E. Y. Oh, et al. (2000). Comparison of Therapeutic Efficacy between Haloperidol and Risperdone in Tic Disirders. Korean College of Neuropsychopharmcology, 11(3), 270-277.
  7. N. Ji & R. L. Findling. (2015). Anupdate on pharmacotherapy for autism Spectrum Disorder in Children and Adolescents. Curr Opin Psychiatry, 28(2), 91-101. https://doi.org/10.1097/yco.0000000000000132
  8. J. S. Choi. (1993). Pharmacological Treatment in pervasive developmental disorders. J. the Korean Academy of Child and Adolescent Psychiatry. 4(1), 27-38.
  9. T. Hayashi et al. (2004). Actual Conditions of Use of Anti-Psychotic Drugs in Institute for People with Intellectual Disabilities. Bulletin of the School of Nursing, Yamaguchi Prefectural University, 8, 1-4.
  10. Y. Ono. (2000). Usage status of psychotropic medication in Mental retardation. Clinical psychiatry, 47(7), 697-703.
  11. H. Nakayama. (2001). A Questionnaire survey on the psychiatric conditions of patients in residential facilities for mentally handicapped children. Japanese Journal of Child and Adolescent Psychiatry. 42(1), 57-65.
  12. K. Tanaka et al. (2006). Clinical Characteristics and Pharmacotherapy of Extremely Disruptive Behavior Disorders in People with Mental Retardation. No To Hattatsu, 38, 19-24.
  13. H. J. Yu. (2018). The clinical approach of mental health to the socially underprivileged such as developmnetal disability etc. Classroon of a psychiatrist in Seoul National University, SHUBH, The psychiatry department, presentation material.
  14. M. S. Kim & H. J., Kim. (2011). Understand and Education of Special Children for Special Education Teacher. Changjisa. 140-146.
  15. D. L. Bowring et al. (2017). Challenging behaviors in adults with intellectual disability: A total poupulation study and exploration of risk indices. Br J Clin Psychol. 56(1). 16-32 https://doi.org/10.1111/bjc.12118
  16. J. Y. Kwon. (2009). Diagnostic Evaluation and Rehabilitation in Children with Intellectual Disabilities. Korean Med Assoc. 52(6), 601-610. https://doi.org/10.5124/jkma.2009.52.6.601
  17. M. Y. Choi. (2009). Health and Medical Care for People With Disability. Health And welfare Forum, 46-63.
  18. M, Weiss et. al. (2009). A naturalistic study of predictors and risks of atypical antipsychotic use in an attention-deficit/hyperactivity disorder clinic. J Child Adolesc Psychopharmacol, 19, 575-582. https://doi.org/10.1089/cap.2009.0050
  19. S. B. Lee et. al. (2016). Differences of obstetric complications and clinical characteristics between autism spectrum disorder and Intellectual Disability. Psychosmatic, 24(2), 165-173.
  20. E. Y. Oh et. al. (2013). Comparison of Therapeutic Efficacy between Haloperidol and Risperidone in Tic Disorders. The Korean Journal of Psychopharmacology, 11(3), 270-277
  21. H. W. Sin. (2011). Recognition of the importance and practice of the assessment of rehabilitation services and therapeutic facilities for disables person. Unpublished master's dissertation, Kwangwoon University.
  22. H. K. Lim(2014). Social Worker's perception of minimum service standards of residental care facilities for the disabled. Unpublished master's dissertation, Ulsan University.
  23. S. K. Park.(2016). The present condition and tasks of deinstitutionalization of the people with disabilities in Korea. Journal of Intellectual Disabilities, 18(1), 205-234.
  24. Y. Inoue et al. (2016). Psychotropic Prescribing Practices for Children and Adolescents with Intellectual Disabilities : A cohort Study Using a Large-Scale Health Insurance Database. Psychiat. neurol. Jap, 118(11), 823-833.
  25. Japanese Association on intellectual & Welfare Disabilities. (2016). National Intellectual Disabilities Report on actual condition of entrance facility. 235-295.
  26. Y. I. Chung & S. H. Park. (2006). Development History of Antipsychotic Drugs. The Korean Journal of Psychopharmacology, 17(3), 283-290.
  27. T. Doan et. al. (2014). Psychotropic medication use in adolescents with intellectual disability living in the community. Pharmacoepidemiol Drug Saf, 23(1), 69-76. https://doi.org/10.1002/pds.3484
  28. I. Kimura et. al.(2016). Treatment for self-injurious in mentally hadicapped populatons -a report from our practice. Hattatsu, 48, 117-121.
  29. S. W, Hsu er. al. (2014). Trends in the use of psychotropic drugs in people with intellectual disability in Taiwan: a nationwide outpatient service study, 1997-2007. Res Dev Disabil., 35(2), 364-372. https://doi.org/10.1016/j.ridd.2013.11.011
  30. J. S. Kwon & K. J. Lee. (2004). Atypical Antipsychotics : The Benefit and Disadvantage. Korean J Psychopharmacol, 15(2), 125-134.
  31. J. W. Park & H. Y. Im.(1993). The Experiences of Antipsychotic Agents in Mentally Disabled. Korean J Str Res, 20, 21-30.